Zura Bio Ltd.
- ZURA · Nasdaq
- Biological Products, (No Diagnostic Substances)
- La Jolla, CA
- 40 employees
- CIK 0001855644
Updated from SEC filings through
Top things to know
Executives
- Sandeep Chidambar Kulkarni Chief Executive Officer Form 4, April 2, 2026
- Eric J. Hyllengren Chief Financial Officer Form 4, April 2, 2026
- Kim Davis Chief Operating Officer, Chief Legal Officer and Corporate Secretary 8-K, May 22, 2026
- Gary Whale Chief Technology Officer Form 4, April 2, 2026
- Marlyn Teresa Mathew VP, Principal Acctg. Officer Form 3, June 22, 2026
- Asim Mohammed BAFFX17 Parties 10-K, March 19, 2026
Zura Bio Ltd is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in La Jolla, CA. It trades as ZURA on Nasdaq. It reported about 40 employees.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | Not on file | Not on file | Not on file | Not on file |
| Operating income | -$75.2M 10-K, 2026-03-19 | -$55.2M 10-K, 2026-03-19 | -$62.6M 10-K, 2025-03-25 | -$2.7M 10-K, 2023-03-28 |
| SG&A | $33.2M 10-K, 2026-03-19 | $30.8M 10-K, 2026-03-19 | $18.6M 10-K, 2025-03-25 | $2.3M 10-K, 2023-03-28 |
| Net income | -$68.7M 10-K, 2026-03-19 | -$52.4M 10-K, 2026-03-19 | -$60.4M 10-K, 2025-03-25 | -$25.7M 10-K, 2024-03-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Sandeep Chidambar Kulkarni | Chief Executive Officer | Form 4, April 2, 2026 |
| Eric J. Hyllengren | Chief Financial Officer | Form 4, April 2, 2026 |
| Kim Davis | Chief Operating Officer, Chief Legal Officer and Corporate Secretary | 8-K, May 22, 2026 |
| Kiran Nistala | Named in proxy bio: Chief Medical Officer and Head of Development | DEF 14A, April 30, 2026 |
| Gary Whale | Chief Technology Officer | Form 4, April 2, 2026 |
| Marlyn Teresa Mathew | VP, Principal Acctg. Officer | Form 3, June 22, 2026 |
| Asim Mohammed | BAFFX17 Parties | 10-K, March 19, 2026 |
| Baljit Lehal | Stone Peach Parties | 10-K, March 19, 2026 |
| Kanwarjeet “Shawn” Tucker | Stone Peach Parties | 10-K, March 19, 2026 |
| Lahmber Singh | BAFFX17 Parties | 10-K, March 19, 2026 |
| Amit D. Munshi | Board member (per proxy) bio: Chairman of our Board | DEF 14A, April 30, 2026 |
| Dan Becker, M.D., Ph.D. | Board member (per proxy) bio: director | DEF 14A, April 30, 2026 |
| Mark Eisner, M.D., M.P.H. | Board member (per proxy) bio: director | DEF 14A, April 30, 2026 |
What Zura Bio Ltd does
We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 96.3 million (as of October 27, 2026) | 10-Q, October 27, 2026 |
|---|---|---|
| Public float | $59.0M (as of June 30, 2025) | 10-K, March 19, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, October 27, 2026 |
| Latest proxy statement | Meeting June 17, 2026 (filed April 30, 2026) | DEF 14A, April 30, 2026 |
| Auditor | WithumSmith+Brown, PC (East Brunswick, New Jersey) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-11-09
- Item 8.01 Other events
- 8-K filed 2026-10-27
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-17
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-11
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-01
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-18
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-22
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-07
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-23
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-19
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Zura Bio Ltd
- What does Zura Bio Ltd do?
- In its own words, from Item 1 of its 10-K: "We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies."
- How many employees does Zura Bio Ltd have?
- About 40 as of December 31, 2025, as stated in its annual report.
- Who is the CFO of Zura Bio Ltd?
- Eric J. Hyllengren, Chief Financial Officer, as named in a 4 filed April 2, 2026.
- Where is Zura Bio Ltd headquartered?
- La Jolla, CA.
- What is Zura Bio Ltd's stock ticker?
- ZURA on Nasdaq.
- What industry is Zura Bio Ltd in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Zura Bio Ltd's website?
- zurabio.com.
- When does Zura Bio Ltd report earnings next?
- February 11, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Zura Bio Ltd a public company?
- Yes. Zura Bio Ltd files with the SEC under CIK 0001855644 and trades as ZURA.
- Who audits Zura Bio Ltd?
- WithumSmith+Brown, PC, East Brunswick, New Jersey, as named in its latest annual report (10-K).
- How many shares of Zura Bio Ltd are outstanding?
- 96.3 million shares as of October 27, 2026, from its 10-Q filed October 27, 2026.
- What is Zura Bio Ltd's public float?
- $59.0M as of June 30, 2025, as reported on the cover of its 10-K filed March 19, 2026.
- How many business segments does Zura Bio Ltd report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed October 27, 2026.
- When is Zura Bio Ltd's annual shareholder meeting?
- June 17, 2026, per its proxy statement (DEF 14A) filed April 30, 2026.